Navigation
Suscribe
Menu Search Facebook Twitter
Search Close
Menu ALL SECTIONS
  • Capital Coahuila
  • Capital Hidalgo
  • Capital Jalisco
  • Capital Morelos
  • Capital Oaxaca
  • Capital Puebla
  • Capital Quintana Roo
  • Capital Querétaro
  • Capital Veracruz
  • Capital México
  • Capital Michoacán
  • Capital Mujer
  • Reporte Índigo
  • Estadio Deportes
  • The News
  • Efekto
  • Diario DF
  • Capital Edo. de Méx.
  • Green TV
  • Revista Cambio
Radio Capital
Pirata FM
Capital Máxima
Capital FM
Digital
Prensa
Radio
TV
X
Newsletter
Facebook Twitter
X Welcome! Subscribe to our newsletter and receive news, data, statistical and exclusive promotions for subscribers
Business

Pfizer on Buying Spree with AstraZeneca Antibiotics Deal

Pfizer had planned that $119 billion acquisition to enable it to slash its U.S. tax bill by moving its nominal headquarters to England

The Pfizer logo is seen at the pharmaceutical company' world headquarters in Manhattan, New York, U.S., photo: Reuters/Andrew Kelly
1 year ago

TRENTON, New Jersey – Drugmaker Pfizer Inc. is continuing its shopping spree with its fourth acquisition since the April collapse of its planned $160 billion megadeal to buy rival Allergan PLC and move its headquarters, on paper, to Allergan’s base in lower-tax Ireland.

In its second deal this week, New York-based Pfizer said it’s buying rights to Anglo-Swedish drugmaker AstraZeneca PLC’s portfolio of approved and experimental antibiotic and antifungal pills, a move to boost Pfizer’s business in one of its priority areas. The deal is valued in excess of $1.5 billion, including rights to sell the medicines in most countries outside the U.S., royalties and other payments.

The acquisition indicates a thawing of relations between the two companies barely two years after London-based AstraZeneca fought off Pfizer’s hostile takeover attempt.

Pfizer had planned that $119 billion acquisition as a so-called “tax inversion” enabling Pfizer to slash its U.S. tax bill by moving its nominal headquarters — but not its corporate offices or executives — to England.

The tax inversion strategy had been hot in corporate United States for a few years, but it’s cooled down since the U.S. Treasury Department in early April issued new tax rules to block the biggest U.S. drugmaker from becoming a corporate citizen of Ireland. Allergan is technically based in Dublin, but it’s the result of a tax inversion merger and operates from Parsippany, New Jersey.

Under the deal announced Wednesday, AstraZeneca will receive an upfront payment of $550 million. Pfizer will get rights to some medicines in development and approved ones including Merrem, for treating bacterial meningitis and serious infections of the skin and stomach; Zinforo, for pneumonia and complex skin and soft tissue infections; and Zavicefta, a combination antibiotic the European Union just approved for treating serious bacterial infections.

Luke Miels, the head of the antibiotics business unit at AstraZeneca, said in a statement the company is “pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases.”

Pfizer’s other recent deals include:

—On Monday, it announced a $14 billion deal to buy San Francisco-based Medivation, which develops pills for treating various cancers. That’s a priority area, but Pfizer is playing catch-up with rivals dominating the new generation of targeted cancer medicines.

—On Aug. 1, Pfizer announced a deal worth $150 million upfront and potentially another $495 million to acquire what Pfizer didn’t already own of Bamboo Therapeutics Inc. of Chapel Hill, North Carolina. It’s is developing potentially lucrative gene therapies for rare diseases. Pfizer aims to become a leader in gene therapy.

—In June, Pfizer completed the $5.2 billion acquisition of Palo Alto, California-based Anacor Pharmaceuticals Inc., which could get a new eczema drug, Crisaborole, approved by January. Pfizer also got topical toenail fungus treatment Kerydin and some other drugs in early testing.

In afternoon trading, Pfizer shares edged up 27 cents to $35.36. Investors seem to like Pfizer’s return to focusing on deals to create new drugs, though. Since Pfizer scrapped the Allergan deal, its shares have jumped more than 12 percent.

LINDA A. JOHNSON

Comments Whatsapp Twitter Facebook Share
More From The News
Latest News

Democrat Jones wins stunning red-state A ...

5 days ago
Business

Asian stocks mixed ahead of Fed rate ann ...

5 days ago
Entertainment

NFL Network suspends analysts over sexua ...

5 days ago
Business

Minnesota announces restrictions on usin ...

5 days ago
Most Popular

IMF Seeks Contingency Plans for Vulnerab ...

By The News
Business

WALMEX Sales Grow 15.6 Percent in Februa ...

By Omar Sánchez
Business

In the Market for a Diamond? Lucky You.

By The News
Business

Brazil's Agnelli, Who Turned Vale Into T ...

By Reuters
Business

Taste for Bacon Spurs Investor Feast as ...

By The News
Business